PALATIN TECHNOLOGIES Forum: Community User: CologneFC

Before Hours Volume: 437K

Mal schauen was um 15:30 geht!

The main objective of the study was to demonstrate release of polymer-bound PL-8177 in the lower gastrointestinal tract after oral administration. Top *** data showed favorable pharmacokinetics, and demonstrated PL-8177 was released in the lower gastrointestinal tract, supporting oral administration of PL-8177 using the delayed release polymer formulation. A secondary objective of the study was also met, demonstrating that PL-8177 is not systemically absorbed after oral administration. There was no intact PL-8177 or its metabolite detected in plasma after oral administration. The oral formulation was well tolerated and there were no adverse events observed. "The results of this study support moving forward with development of polymer-bound PL-8177 to deliver drug to the lower gastrointestinal tract to treat ulcerative colitis and other inflammatory bowel diseases," said Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies. "Importantly, this study demonstrates that our oral, delayed-release polymer formulation of PL-8177 can deliver peptide to the diseased region of the bowel, without systemic uptake. The melanocortin receptor 1 is a novel target for treating ulcerative colitis and other inflammatory diseases, as it is present on the interior wall, or lumen, of the colon and lower gastrointestinal tract." The lumen of the colon and lower gastrointestinal tract contains cells with receptors for melanocortin-1, which when activated by binding of PL-8177 can result in resolution of chronic inflammatory responses. The delayed release polymer formulation of PL-8177 is designed to protect the peptide until it reaches the lower gastrointestinal tract. This open label study enrolled 24 subjects divided into 6 cohorts of 4 patients each. Blood, urine and feces samples were analyzed for total radioactivity and radiolabeled PL-8177 and its metabolite. The percentage of intact radiolabeled PL-8177 and its metabolite was measured at different timepoints following administration of a single oral microdose of polymer-bound radiolabeled PL-8177. About PL-8177 Evolving research suggests that the melanocortin receptor 1 (MC1r) system plays an important role in anti-inflammatory responses and immunoregulation, including resolution of innate pro-inflammatory immune responses. PL-8177 is Palatin's lead clinical development candidate for ulcerative colitis and other inflammatory bowel diseases. PL-8177, a selective MC1r agonist peptide, is a synthetic cyclic heptapeptide with demonstrated efficacy in animal inflammatory bowel disease models. PL-8177 is a potent agonist at human MC1r, with sub-nanomolar affinity binding and EC50 functional values.

Jetzt noch positive die Daten zur Prüfung des Blutdrucks bei unserem aktuellen medi und es kann richtig losgehen

Jetzt hab ich’s au grad auf der hp gefunden !!! Sehr gut

Palatin Technologies Announces Positive Top *** Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases

Wird wohl neue Infos geben ... hab aber keine gefunden auf die Schnelle

1 € :)

Wow, jetzt steigt es extrem schnell!

Hält sich wacker...hoffentlich kommen bald positive news zur Kurzstudie. Dann geht's weiter rauf.

Bin gespannt ob PT diese Woche die 90cent knackt und hält. Langsam kommen wir doch in die heiße Phase...

Freitags FOMO lässt grüßen!

Was geht denn heute hier ab? Gab es news?

"Nur" noch 2 1|2 Monate.

Lasset die Spiele beginnen!

... dem ist eigentlich nichts hinzuzufügen 👍 (auch bei CUV ist das Ende der Fahnenstange noch nicht in Sicht und das Chartbild sucht seinesgleichen)